<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kpccz</journal-id><journal-title-group><journal-title xml:lang="ru">Комплексные проблемы сердечно-сосудистых заболеваний</journal-title><trans-title-group xml:lang="en"><trans-title>Complex Issues of Cardiovascular Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-1278</issn><issn pub-type="epub">2587-9537</issn><publisher><publisher-name>Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17802/2306-1278-2026-15-4-6-21</article-id><article-id custom-type="elpub" pub-id-type="custom">kpccz-1976</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ. Кардиология. Рентгенэндоваскулярная хирургия</subject></subj-group></article-categories><title-group><article-title>АССОЦИАЦИЯ ПОЛИМОРФИЗМА T1565C (RS5918) ГЕНА ИНТЕГРИНА БЕТА-3 (ITGB3) С ХАРАКТЕРИСТИКАМИ ВМЕШАТЕЛЬСТВ, ПЕРИПРОЦЕДУРНЫМИ ОСЛОЖНЕНИЯМИ И ОТДАЛЕННЫМ ПРОГНОЗОМ ПОСЛЕ ПЛАНОВОЙ ЭНДОВАСКУЛЯРНОЙ РЕВАСКУЛЯРИЗАЦИИ МИОКАРДА</article-title><trans-title-group xml:lang="en"><trans-title>ASSOCIATION OF THE T1565C (RS5918) POLYMORPHISM IN THE INTEGRINE-Β3 (ITGB3) GENE WITH INTERVENTION CHARACTERISTICS, PERIPROCEDURAL COMPLICATIONS, AND LONG-TERM PROGNOSIS AFTER PLANNED ENDOVASCULAR MYOCARDIAL REVASCULARIZATION Running title: ITGB3 polymorphism: interventions, complications, and prognosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2665-9108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Налесник</surname><given-names>Елена Олеговна</given-names></name><name name-style="western" xml:lang="en"><surname>Nalesnik</surname><given-names>Elena O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук научный сотрудник лаборатории регистров сердечно-сосудистых заболеваний, высокотехнологичных вмешательств и телемедицины Научно-исследовательского института кардиологии – филиала Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук», Томск, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Researcher at the Laboratory of Cardiovascular Disease Registries, High-Tech Interventions, and Telemedicine of the Cardiology Research Institute, Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”, Tomsk, Russian Federation</p></bio><email xlink:type="simple">oliver@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7361-2161</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муслимова</surname><given-names>Эльвира Фаритовна</given-names></name><name name-style="western" xml:lang="en"><surname>Muslimova</surname><given-names>Elvira F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук научный сотрудник лаборатории молекулярно-клеточной патологии и генодиагностики Научно-исследовательского института кардиологии – филиала Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук», Томск, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Researcher at the Laboratory of Molecular Cell Pathology and Genodiagnostics of the Cardiology Research Institute, Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”, Tomsk, Russian Federation</p></bio><email xlink:type="simple">muslimova@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0211-4525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кавешников</surname><given-names>Владимир Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Kaveshnikov</surname><given-names>Vladimir S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук ведущий научный сотрудник, исполняющий обязанности заведующего лабораторией регистров сердечно-сосудистых заболеваний, высокотехнологичных вмешательств и телемедицины Научно-исследовательского института кардиологии – филиала Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук», Томск, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Leading Researcher, Acting Head of the Laboratory of Cardiovascular Disease Registries of the Cardiology Research Institute, Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”, Tomsk, Russian Federation</p></bio><email xlink:type="simple">kv@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6066-3998</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьев</surname><given-names>Сергей Александрович</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasiev</surname><given-names>Sergei A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских нуаук профессор заведующий лабораторией молекулярно-клеточной патологии и генодиагностики Научно-исследовательского института кардиологии – филиала Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук», Томск, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, MD, Рrofessor, Head of the Laboratory of Molecular Cell Pathology and Genodiagnostics of the Cardiology Research Institute, Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”, Tomsk, Russian Federation</p></bio><email xlink:type="simple">tursky@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук», «Научно-исследовательский институт кардиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>04</day><month>09</month><year>2026</year></pub-date><volume>15</volume><issue>4</issue><fpage>6</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Налесник Е.О., Муслимова Э.Ф., Кавешников В.С., Афанасьев С.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Налесник Е.О., Муслимова Э.Ф., Кавешников В.С., Афанасьев С.А.</copyright-holder><copyright-holder xml:lang="en">Nalesnik E.O., Muslimova E.F., Kaveshnikov V.S., Afanasiev S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nii-kpssz.com/jour/article/view/1976">https://www.nii-kpssz.com/jour/article/view/1976</self-uri><abstract><sec><title>Основные положения</title><p>Основные положения</p></sec><sec><title> </title><p> </p></sec><sec><title>Цель</title><p>Цель. Изучить ассоциацию полиморфизма T1565C (rs5918) гена ITGB3 с характеристиками вмешательств, перипроцедурными осложнениями и отдаленным прогнозом пациентов после плановой эндоваскулярной реваскуляризации миокарда.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. У 364 пациентов, которым было выполнено плановое чрескожное коронарное вмешательство (ЧКВ), определили полиморфные варианты T1565C (rs5918) гена ITGB3, изучили особенности поражения коронарного русла и выполненных вмешательств, а также оценили частоту острых осложнений, отдаленных (5-летних) неблагоприятных событий и динамику функции почек в отдаленный период в группах пациентов с различными генотипами полиморфизма rs5918 гена ITGB3. Для оценки ассоциации данного полиморфизма с конечными точками использовали таблицы сопряженности с расчетом ОШ.</p></sec><sec><title>Результаты</title><p>Результаты. Минорный аллель 1565С и генотип 1565СС ассоциированы с более частыми гемодинамически значимыми стенозами ствола левой коронарной артерии (4,4, 6,9 и 30% в группах ТТ, ТС и СС, соответственно, р = 0,003) и передней нисходящей артерии (79, 66,7 и 100% в группах ТТ, ТС и СС, соответственно, р = 0,01), более частым достижением полной реваскуляризации миокарда (54,4, 70,6, 70% в группах ТТ, ТС и СС, соответственно, р = 0,01) и более низкий остаточный индекс SYNTAX (4,1 ± 6,7 (0–43,5); 2,9 ± 6,2 (0–28,5) и 2,4 ± 4,6 (0–14) в группах ТТ, ТС и СС, соответственно, р = 0,02) при имплантации меньшего количества стентов. Кроме того, выявлена ассоциация минорного генотипа 1565СС с острым перипроцедурным повреждением почек (ОШ 7 200; 95% ДИ [1,827–28,379], р = 0,011) и ухудшением функции почек через 5 лет после индексного ЧКВ (скорость клубочковой фильтрации ≤ 60 мл/мин/1,73 м2 у 19, 36 и 40% в группах ТТ, ТС и СС, соответственно, р = 0,04).</p></sec><sec><title>Заключение</title><p>Заключение. В условиях применения двойной антиагрегантной терапии, подобранной с учетом остаточной реактивности тромбоцитов по данным агрегатограммы, не выявлено ассоциации полиморфизма T1565C (rs5918) гена ITGB3 с острым перипроцедурным повреждением миокарда и отдаленными сердечно-сосудистыми осложнениями. Полиморфизм T1565C (rs5918) ассоциирован с острым перипроцедурным повреждением почек и снижением почечной функции в отдаленный период.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Highlights</title><p>Highlights</p></sec><sec><title> </title><p> </p></sec><sec><title>Aim</title><p>Aim. To study the association of the T1565C (rs5918) polymorphism in the ITGB3 gene with the characteristics of interventions, periprocedural complications and long-term prognosis of patients after elective endovascular myocardial revascularization.</p></sec><sec><title>Methods</title><p>Methods. Polymorphic variants of the single nucleotide polymorphism T1565C (rs5918) in the ITGB3 gene were identified in 364 patients undergoing elective PCI. We studied the characteristics of coronary artery disease and the interventions performed, and also assessed the frequency of acute complications, late (5-year) adverse events, and the dynamics of renal function in the acute and late periods in groups of patients with different genotypes of the rs5918 polymorphism in the ITGB3 gene. Contingency tables and odds ratio (OR) calculations were used to assess the association of this polymorphism with endpoints.</p></sec><sec><title>Results</title><p>Results. The minor allele 1565C and the 1565CC of the polymorphism T1565C (rs5918) in the ITGB3 gene genotype are associated with more frequent hemodynamically significant stenosis of the left main coronary artery (4.4, 6.9 and 30% in the TT, TC and CC groups, respectively, p = 0.003) and the anterior descending artery (79, 66.7 and 100% in the TT, TC and CC groups, respectively, p = 0.01), more frequent achievement of complete myocardial revascularization (54.4, 70.6, 70% in the TT, TC and CC groups, respectively, p = 0.01) and a lower residual SYNTAX index (4.1 ± 6.7 (0–43.5); 2.9 ± 6.2 (0–28.5) and 2.4 ± 4.6 (0–14) in the TT, TC and CC groups, respectively, p = 0.02) with implantation of a smaller number of stents. In addition, an association was found between the minor 1565CC genotype with acute periprocedural kidney injury (OR 7.200; 95% CI [1.827–28.379], p = 0.011) and deterioration of renal function 5 years after index PCI (SCF ≤ 60 ml/min/1.73 m2 in 19, 36 and 40% in the TT, TC and CC groups, respectively, p = 0.04).</p></sec><sec><title>Conclusion</title><p>Conclusion. Under conditions of dual antiplatelet therapy, selected taking into account the residual platelet reactivity according to the aggregogram data, no association was found between the T1565C (rs5918) polymorphism in the ITGB3 gene and acute periprocedural myocardial injury and long-term cardiovascular complications. Polymorphism rs5918 in the ITGB3 gene is associated with acute periprocedural kidney injury and decreased renal function in the late period.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Стабильная ишемическая болезнь сердца</kwd><kwd>Плановое чрескожное коронарное вмешательство</kwd><kwd>Полиморфизм T1565C (rs5918) гена ITGB3</kwd><kwd>Острое перипроцедурное повреждение почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Stable coronary artery disease</kwd><kwd>Elective percutaneous coronary intervention</kwd><kwd>T1565C (rs5918) polymorphism in the ITGB3 gene</kwd><kwd>Acute periprocedural kidney injury</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках Государственного задания Министерства науки и высшего образования № 122020300040-0.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann F.J., Sousa-Uva M., Ahlsson A., et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.</mixed-citation><mixed-citation xml:lang="en">Neumann F.J., Sousa-Uva M., Ahlsson A., et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas S., Gokhale R., Boden W.E., et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol. 2013;29(4):472-82. doi: 10.1016/j.cjca.2012.07.010.</mixed-citation><mixed-citation xml:lang="en">Thomas S., Gokhale R., Boden W.E., et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol. 2013;29(4):472-82. doi: 10.1016/j.cjca.2012.07.010.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Lamee R., Thompson D., Dehbi H.M., et al; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9.</mixed-citation><mixed-citation xml:lang="en">Al-Lamee R., Thompson D., Dehbi H.M., et al; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Derington C.G., Heath L.J., Kao D.P., et al. Validation of algorithms to identify elective percutaneous coronary interventions in administrative databases. PLoS One. 2020;15(4):e0231100. doi: 10.1371/journal.pone.0231100.</mixed-citation><mixed-citation xml:lang="en">Derington C.G., Heath L.J., Kao D.P., et al. Validation of algorithms to identify elective percutaneous coronary interventions in administrative databases. PLoS One. 2020;15(4):e0231100. doi: 10.1371/journal.pone.0231100.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Налесник Е.О., Репин А.Н. Предикторы острого перипроцедурного повреждения миокарда при плановых чрескожных коронарных вмешательствах. Атеросклероз и дислипидемии. 2024;3(56):21–44. doi: 10.34687/2219-8202.JAD.2024.03.0003.</mixed-citation><mixed-citation xml:lang="en">Nalesnik E.O., Repin A.N. Predictors of acute periprocedural myocardial injury during elective percutaneous coronary interventions. Atherosclerosis and dyslipidemias. 2024;3(56):21–44. doi: 10.34687/2219-8202.JAD.2024.03.0001.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Налесник Е.О., Репин А.Н. Оценка риска отдаленных смертельных сердечно-сосудистых событий у пациентов с хроническим коронарным синдромом после эндоваскулярной реваскуляризации миокарда. Комплексные проблемы сердечно-сосудистых заболеваний. 2022;11(3): 40-50. doi: 10.17802/2306-1278-2022-11-3-40-50.</mixed-citation><mixed-citation xml:lang="en">Nalesnik E.O., Repin A.N. Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. Complex Issues of Cardiovascular Diseases. 2022;11(3):40-50. (In Russ.) doi: 10.17802/2306-1278-2022-11-3-40-50.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61(3):498-511. doi: 10.1016/j.cardiores.2003.11.036.</mixed-citation><mixed-citation xml:lang="en">Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61(3):498-511. doi: 10.1016/j.cardiores.2003.11.036.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Huang, J., Li, X., Shi, X. et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. Journal of Hematology &amp; Oncology. 2019;12(1):26. doi: 10.1186/s13045-019-0709-6</mixed-citation><mixed-citation xml:lang="en">Huang, J., Li, X., Shi, X. et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. Journal of Hematology &amp; Oncology. 2019;12(1):26. doi: 10.1186/s13045-019-0709-6</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Newman P.J., Derbes R.S., Aster R.H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83(5):1778-81. doi: 10.1172/JCI114082.</mixed-citation><mixed-citation xml:lang="en">Newman P.J., Derbes R.S., Aster R.H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83(5):1778-81. doi: 10.1172/JCI114082.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Todinova S., Komsa-Penkova R., Krumova S., et al. PlA2 Polymorphism in Glycoprotein IIb/IIIa Modulates the Morphology and Nanomechanics of Platelets. Clin Appl Thromb Hemost. 2017;23(8):951-960. doi: 10.1177/1076029616687847</mixed-citation><mixed-citation xml:lang="en">Todinova S., Komsa-Penkova R., Krumova S., et al. PlA2 Polymorphism in Glycoprotein IIb/IIIa Modulates the Morphology and Nanomechanics of Platelets. Clin Appl Thromb Hemost. 2017;23(8):951-960. doi: 10.1177/1076029616687847</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Floyd C.N., Ellis B.H., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One. 2014;9(7):e100239. doi: 10.1371/journal.pone.0100239.</mixed-citation><mixed-citation xml:lang="en">Floyd C.N., Ellis B.H., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One. 2014;9(7):e100239. doi: 10.1371/journal.pone.0100239.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Floyd C.N., Mustafa A., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One. 2014;9(7):e101518. doi: 10.1371/journal.pone.0101518.</mixed-citation><mixed-citation xml:lang="en">Floyd C.N., Mustafa A., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One. 2014;9(7):e101518. doi: 10.1371/journal.pone.0101518.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Montagnana M., Danese E., Lippi G. Genetic risk factors of atherothrombosis. Pol Arch Med Wewn. 2014;124(9):474-82. doi: 10.20452/pamw.2409.</mixed-citation><mixed-citation xml:lang="en">Montagnana M., Danese E., Lippi G. Genetic risk factors of atherothrombosis. Pol Arch Med Wewn. 2014;124(9):474-82. doi: 10.20452/pamw.2409.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Floyd C.N., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446-57. doi: 10.1111/bcp.12204.</mixed-citation><mixed-citation xml:lang="en">Floyd C.N., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446-57. doi: 10.1111/bcp.12204.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О.Л., Карпов Ю.А., Кашталап В.В., Бощенко А.А., Руда М.М. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25:4076. doi: 10.15829/1560-4071-2020-4076.</mixed-citation><mixed-citation xml:lang="en">Barbarash O. L., Karpov Yu. A., Kashtalap V. V.*, Boschenko A. A., Ruda M. M. et al. 2020 Clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020;25:4076. DOI: 10.15829/1560-4071-2020-4076. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K., Alpert J.S., Jaffe A.S., et al; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. doi: 10.1093/eurheartj/ehy462.</mixed-citation><mixed-citation xml:lang="en">Thygesen K., Alpert J.S., Jaffe A.S., et al; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. doi: 10.1093/eurheartj/ehy462.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kellum J.A., Lameire N.; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204. doi: 10.1186/cc11454.</mixed-citation><mixed-citation xml:lang="en">Kellum J.A., Lameire N.; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204. doi: 10.1186/cc11454.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393–1399. doi: 10.1016/j.jacc.2004.06.068.</mixed-citation><mixed-citation xml:lang="en">Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393–1399. doi: 10.1016/j.jacc.2004.06.068.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lawton J., Tamis-Holland J., Bangalore S., et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022. Vol. 79, № 2. P. 21–129. doi: 10.1016/j.jacc.2021.09.006.</mixed-citation><mixed-citation xml:lang="en">Lawton J., Tamis-Holland J., Bangalore S., et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022. Vol. 79, № 2. P. 21–129. doi: 10.1016/j.jacc.2021.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Floyd C.N., Ferro A., Warner T.D. Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovascular Disease. 2015;4:2048004015610252. doi: 10.1177/2048004015610252.</mixed-citation><mixed-citation xml:lang="en">Floyd C.N., Ferro A., Warner T.D. Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovascular Disease. 2015;4:2048004015610252. doi: 10.1177/2048004015610252.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Strisciuglio T., Franco D., Di Gioia G., et al. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovascular Diagnosis and Therapy. 2018;8(5):610-620. doi: 10.21037/cdt.2018.05.06.</mixed-citation><mixed-citation xml:lang="en">Strisciuglio T., Franco D., Di Gioia G., et al. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovascular Diagnosis and Therapy. 2018;8(5):610-620. doi: 10.21037/cdt.2018.05.06.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cayla G., Hulot J.S., O'Connor S.A., et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765-74. doi: 10.1001/jama.2011.1529.</mixed-citation><mixed-citation xml:lang="en">Cayla G., Hulot J.S., O'Connor S.A., et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765-74. doi: 10.1001/jama.2011.1529.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jastrzebska M., Lisman D., Szelepajlo A., et al. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. J Physiol Pharmacol. 2019;70(2). doi: 10.26402/jpp.2019.2.01.</mixed-citation><mixed-citation xml:lang="en">Jastrzebska M., Lisman D., Szelepajlo A., et al. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. J Physiol Pharmacol. 2019;70(2). doi: 10.26402/jpp.2019.2.01.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kastrati A., Schömig A., Seyfarth M., et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999 Mar 2;99(8):1005-10. doi: 10.1161/01.cir.99.8.1005.</mixed-citation><mixed-citation xml:lang="en">Kastrati A., Schömig A., Seyfarth M., et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999 Mar 2;99(8):1005-10. doi: 10.1161/01.cir.99.8.1005.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Walter D.H., Schächinger V., Elsner M., et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350(9086):1217-9. doi: 10.1016/s0140-6736(97)05399-3.</mixed-citation><mixed-citation xml:lang="en">Walter D.H., Schächinger V., Elsner M., et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350(9086):1217-9. doi: 10.1016/s0140-6736(97)05399-3.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hoppmann P., Koch W., Laugwitz K.L., et al. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coron Artery Dis. 2014;25(8):658-64. doi: 10.1097/MCA.0000000000000149.</mixed-citation><mixed-citation xml:lang="en">Hoppmann P., Koch W., Laugwitz K.L., et al. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coron Artery Dis. 2014;25(8):658-64. doi: 10.1097/MCA.0000000000000149.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Motovska Z., Kvasnicka J., Hajkova J., et al. Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis. 2010;212(2):548-52. doi: 10.1016/j.atherosclerosis.2010.07.006.</mixed-citation><mixed-citation xml:lang="en">Motovska Z., Kvasnicka J., Hajkova J., et al. Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis. 2010;212(2):548-52. doi: 10.1016/j.atherosclerosis.2010.07.006.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Калесник М. В. Генетические предикторы развития острого почечного повреждения. Журнал Гродненского государственного медицинского университета. 2022;20(5): 479-484. doi: 10.25298/2221-8785-2022-20-5-479-484.</mixed-citation><mixed-citation xml:lang="en">Kalesnik M.V. Genetic predictors of acute kidney injury development. Journal of Grodno State Medical University. 2022;20(5): 479-484. doi: 10.25298/2221-8785-2022-20-5-479-484. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nazirova V., Ismibayli Z., Gafarov I., et al. Association of ITGA2 C807T and ITGB3 T1565C polymorphisms with platelet characteristics in hypertensive Azerbaijani patients. Glob Cardiol Sci Pract. 2025;2025(3):e202528. doi: 10.21542/gcsp.2025.28.</mixed-citation><mixed-citation xml:lang="en">Nazirova V., Ismibayli Z., Gafarov I., et al. Association of ITGA2 C807T and ITGB3 T1565C polymorphisms with platelet characteristics in hypertensive Azerbaijani patients. Glob Cardiol Sci Pract. 2025;2025(3):e202528. doi: 10.21542/gcsp.2025.28.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Головченко О.В., Пономаренко И.В., Чурносов М.И. Полиморфизм rs5918 гена ITGB3 повышает риск развития преэклампсии у беременных с задержкой роста плода. Гинекология. 2021;23(4):330–334. doi: 10.26442/20795696.2021.4.200863.</mixed-citation><mixed-citation xml:lang="en">Golovchenko O.V., Ponomarenko I.V., Churnosov M.I. The rs5918 polymorphism in the ITGB3 gene increases the risk for preeclampsia in pregnant women with fetal growth retardation. Gynecology. 2021;23(4):330–334. doi: 10.26442/20795696.2021.4.200863. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Helmer P., Damm E., Schiekofer S., et al. β3-integrin Leu33Pro gain of function variant does not modulate inflammatory activity in human derived macrophages in diabetes. Int J Med Sci. 2021;18(12):2661-2665. doi: 10.7150/ijms.55648.</mixed-citation><mixed-citation xml:lang="en">Helmer P., Damm E., Schiekofer S., et al. β3-integrin Leu33Pro gain of function variant does not modulate inflammatory activity in human derived macrophages in diabetes. Int J Med Sci. 2021;18(12):2661-2665. doi: 10.7150/ijms.55648.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Staeck O., Slowinski T., Lieker I., et al. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation. 2015;99(12):2593-7. doi: 10.1097/TP.0000000000000914.</mixed-citation><mixed-citation xml:lang="en">Staeck O., Slowinski T., Lieker I., et al. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation. 2015;99(12):2593-7. doi: 10.1097/TP.0000000000000914.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Maile L.A., Busby W.H., Gollahon K.A., et al. Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology. 2014;155(12):4665-75. doi: 10.1210/en.2014-1318.</mixed-citation><mixed-citation xml:lang="en">Maile L.A., Busby W.H., Gollahon K.A., et al. Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology. 2014;155(12):4665-75. doi: 10.1210/en.2014-1318.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Налесник Е.О., Муслимова Э.Ф., Афанасьев С.А., с соавт. Ассоциация полиморфизма T1565C (rs5918) гена ITGB3 с клиническими характеристиками, анатомическими особенностями и отдаленными неблагоприятными событиями у пациентов с хронической ишемической болезнью сердца после плановых эндоваскулярных коронарных вмешательств. Сибирский журнал клинической и экспериментальной медицины. 2026;41(2):176-183. https://doi.org/10.29001/2073-8552-2026-41-2-176-183</mixed-citation><mixed-citation xml:lang="en">Nalesnik E.O., Muslimova E.F., Afanasiev S.A., et al. Association of the T1565C (rs5918) polymorphism of the ITGB3 gene with clinical characteristics, anatomical features and long-term adverse events in patients with chronic coronary artery disease after elective endovascular coronary interventions. Siberian Journal of Clinical and Experimental Medicine. 2026;41(2):176-183. (In Russ.) https://doi.org/10.29001/2073-8552-2026-41-2-176-183</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Janus-Bell E., Mangin P.H. The relative importance of platelet integrins in hemostasis, thrombosis and beyond. Haematologica. 2023;108(7):1734-1747. doi: 10.3324/haematol.2022.282136.</mixed-citation><mixed-citation xml:lang="en">Janus-Bell E., Mangin P.H. The relative importance of platelet integrins in hemostasis, thrombosis and beyond. Haematologica. 2023;108(7):1734-1747. doi: 10.3324/haematol.2022.282136.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zoppi N., Chiarelli N., Ritelli M., et al. Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts. Int J Mol Sci. 2018;19(4):982. doi: 10.3390/ijms19040982.</mixed-citation><mixed-citation xml:lang="en">Zoppi N., Chiarelli N., Ritelli M., et al. Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts. Int J Mol Sci. 2018;19(4):982. doi: 10.3390/ijms19040982.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
